Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 16, 2023

Rhea-AI Summary

Organon (NYSE: OGN), a global women’s healthcare company, will announce its fourth quarter and full year 2022 financial results on February 16, 2023, before its conference call at 8:30 a.m. EST. The call will be accessible via a live webcast on the Organon website, with a replay available two hours post-event. Institutional investors must register in advance to participate, allowing them to join without operator assistance. Organon focuses on women's health, featuring over 60 products, and is positioned for growth through collaboration with biopharmaceutical innovators in international markets.

JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global women’s healthcare company will release its fourth quarter and full year 2022 financial results on February 16, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EST.

Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/. A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company’s website.

Institutional investors and analysts interested in participating in the call must register in advance by clicking on this link: https://conferencingportals.com/event/ZGyfDfjk.

Following registration, participants will receive a confirmation email containing details on how to join the conference call, including dial-in information and a unique passcode and registrant ID. Pre-registration will allow participants to bypass an operator and be placed directly into the call.

About Organon
Organon is a global healthcare company with a focus on improving the health of women throughout their lives. Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the women’s health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in innovation and future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.

For more information, visit http://www.organon.com and connect with us on LinkedIn, Instagram, Twitter and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230206005119/en/

Organon Media:

Karissa Peer

(614) 314-8094

Kate Vossen

(732) 675-8448

Organon Investors:

Jennifer Halchak

(201) 275-2711

Alex Arzeno

(203) 550-3972

Source: Organon & Co.

FAQ

When will Organon release its fourth quarter results for 2022?

Organon will release its fourth quarter and full year 2022 financial results on February 16, 2023.

What time is Organon's conference call scheduled for February 16, 2023?

The conference call is scheduled for 8:30 a.m. EST on February 16, 2023.

How can I access Organon's financial results conference call?

Interested parties can access the live call via webcast on the Organon website.

Do institutional investors need to register for the conference call?

Yes, institutional investors must register in advance to participate in the call.

What is Organon's focus as a company?

Organon focuses on improving women's health with a portfolio of over 60 medicines and products.